# Repeat Dose Safety Study of NRL-1 in Epilepsy Subjects

> **NCT02721069** · PHASE3 · COMPLETED · sponsor: **Neurelis, Inc.** · enrollment: 175 (actual)

## Conditions studied

- Acute Repetitive Seizures
- Breakthrough Seizures

## Interventions

- **DRUG:** NRL-1

## Key facts

- **NCT ID:** NCT02721069
- **Lead sponsor:** Neurelis, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-11
- **Primary completion:** 2020-06-17
- **Final completion:** 2020-07-23
- **Target enrollment:** 175 (ACTUAL)
- **Last updated:** 2022-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02721069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02721069, "Repeat Dose Safety Study of NRL-1 in Epilepsy Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02721069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*